Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects

Best Practice and Research: Clinical Rheumatology

Volumn 27, Issue 3, 2013, Pages 309-318

  Nuttall, Anna ^a   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Activity; Assessment; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BLISIBIMOD; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPRATUZUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TABALUMAB;

ARTICLE; AUTOIMMUNE DISEASE; BRITISH ISLES LUPUS ASSESSMENT INDEX; CLINICAL RESEARCH; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE MARKER; DRUG DOSE INCREASE; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT INDEX; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HUMAN; KRUPP FATIGUE SEVERITY SCALE; LUPUS ACTIVITY INDEX; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SELENA SLEDAI SCORE; SHORT FORM 36; SLEDAI; SLEDAI FLARE INDEX; SYSTEMIC DISEASE; SYSTEMIC LUPUS ACTIVITY MEASURE REVISED; SYSTEMIC LUPUS ACTIVITY QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYUSTEMIC LUPUS ERYTHEMATOSUS SPECIFIC QUALITY OF LIFE; TREATMENT RESPONSE;

ACTIVITY; ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE;

EID: 85027950276     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2013.10.003     Document Type: Review

References (88)

1. M. Petri Hopkins lupus cohort. 1999 update Rheumatic Disease Clinics of North America 26 2 2000 May 199 213
2. J. Romero-Diaz, D. Isenberg, and R. Ramsey-Goldman Measures of adult systemic lupus erythematosus: updated version of British Isles lupus assessment group (BILAG 2004), European consensus lupus activity measurements (ECLAM), systemic lupus activity measure, revised (SLAM-R), systemic lupus activity questionnaire for population studies (SLAQ), systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K), and systemic lupus international collaborating Clinics/American College of Rheumatology damage index (SDI) Arthritis Care & Research (Hoboken) 63 Suppl. 11 2011 Nov S37 S46
3. B. Griffiths, M. Mosca, and C. Gordon Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices Best Practice & Research Clinical Rheumatology 19 5 2005 Oct 685 708
4. A.F. Kavanaugh, and D.H. Solomon Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests Arthritis & Rheumatism 47 5 2002 Oct 15 546 555
5. N. Villegas-Zambrano, V.M. Martinez-Taboada, A. Bolivar, M.M. San, L. Alvarez, and M.J. Marin Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: an eight-year prospective study Annals of the New York Academy of Sciences 1173 2009 Sep 60 66
6. C.C. Mok, D.J. Birmingham, L.Y. Ho, L.A. Hebert, H. Song, and B.H. Rovin Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q Lupus 21 1 2012 Jan 36 42
7. N. Bizzaro, D. Villalta, D. Giavarina, and R. Tozzoli Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis Autoimmunity Reviews 12 2 2012 Dec 97 106
8. O.A. Gutierrez-Adrianzen, S. Koutouzov, R.M. Mota, M.M. das Chagas Medeiros, J.F. Bach, and C.H. de Holanda Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies The Journal of Rheumatology 33 8 2006 Aug 1538 1544
9. J.A. Simon, J. Cabiedes, E. Ortiz, J. cocer-Varela, and J. Sanchez-Guerrero Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker Rheumatology (Oxford) 43 2 2004 Feb 220 224
10. J.D. Reveille Predictive value of autoantibodies for activity of systemic lupus erythematosus Lupus 13 5 2004 290 297
11. D.A. Isenberg Rhubarb and reliability - a Jane Austen view of systemic lupus erythematosus The Journal of Rheumatology 40 1 2013 Jan 7 8
12. D.D. Gladman, D. Ibanez, and M.B. Urowitz Systemic lupus erythematosus disease activity index 2000 The Journal of Rheumatology 29 2 2002 Feb 288 291
13. Z. Touma, M.B. Urowitz, D. Ibanez, and D.D. Gladman SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation Lupus 20 1 2011 Jan 67 70
14. K.C. Kalunian, J.C. Davis Jr., J.T. Merrill, M.C. Totoritis, and D. Wofsy Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial Arthritis & Rheumatism 46 12 2002 Dec 3251 3258
15. C.C. Mok, D.J. Birmingham, L.Y. Ho, L.A. Hebert, and B.H. Rovin High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus Arthritis Care & Research (Hoboken) 65 3 2013 Mar 441 447
16. M.L. Hermansen, L. Hummelshoj, D. Lundsgaard, L. Hornum, P. Keller, and J. Fleckner Increased serum beta2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients Lupus 21 10 2012 Sep 1098 1104
17. M.K. Salama, F.M. Taha, M. Safwat, H.E. Darweesh, and M.E. Basel The Tie2 receptor antagonist angiopoietin-2 in systemic lupus erythematosus: its correlation with various disease activity parameters Immunological Investigations 41 8 2012 864 875
18. R. Mu, X.Y. Sun, L.T. Lim, C.H. Xu, C.X. Dai, and Y. Su Toll-like receptor 9 is correlated to disease activity in Chinese systemic lupus erythematosus population Chinese Medical Journal (England) 125 16 2012 Aug 2873 2877
19. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4 Rheumatology International 32 8 2012 Aug 2445 2451
20. A. Ho, S.G. Barr, L.S. Magder, and M. Petri A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus Arthritis & Rheumatism 44 10 2001 Oct 2350 2357
21. M. Petri, D. Hellmann, and M. Hochberg Validity and reliability of lupus activity measures in the routine clinic setting The Journal of Rheumatology 19 1 1992 Jan 53 59
22. W. Bencivelli, C. Vitali, D.A. Isenberg, J.S. Smolen, M.L. Snaith, and M. Sciuto Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE Clinical and Experimental Rheumatology 10 5 1992 Sep 549 554
23. C.N. Pisoni, F.J. Sanchez, Y. Karim, M.J. Cuadrado, D.P. D'Cruz, and I.C. Abbs Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients The Journal of Rheumatology 32 6 2005 Jun 1047 1052
24. M. Benucci, F.L. Gobbi, R.A. Del, S. Cesaretti, L. Niccoli, and F. Cantini Disease activity and antinucleosome antibodies in systemic lupus erythematosus Scandinavian The Journal of Rheumatology 32 1 2003 42 45
25. M. Mosca, W. Bencivelli, C. Vitali, P. Carrai, R. Neri, and S. Bombardieri The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus Lupus 9 6 2000 445 450
26. S.C. Bae, H.K. Koh, D.K. Chang, M.H. Kim, J.K. Park, and S.Y. Kim Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus Lupus 10 6 2001 405 409
27. R. Willis, A.M. Seif, G. McGwin Jr., L.A. Martinez-Martinez, E.B. Gonzalez, and N. Dang Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort Lupus 21 8 2012 Jul 830 835
28. J. Zhang, L.A. Gonzalez, J.M. Roseman, L.M. Vila, J.D. Reveille, and G.S. Alarcon Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX Lupus 19 6 2010 May 727 733
29. M.I. Danila, G.J. Pons-Estel, J. Zhang, L.M. Vila, J.D. Reveille, and G.S. Alarcon Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort Rheumatology (Oxford) 48 5 2009 May 542 545
30. J. Yazdany, E.H. Yelin, P. Panopalis, L. Trupin, L. Julian, and P.P. Katz Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort Arthritis & Rheumatism 59 1 2008 Jan 15 136 143
31. A.D. Askanase, I. Castrejon, and T. Pincus Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms The Journal of Rheumatology 38 7 2011 Jul 1309 1316
32. F. Wolfe, M. Petri, G.S. Alarcon, J. Goldman, E.F. Chakravarty, and R.S. Katz Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity The Journal of Rheumatology 36 1 2009 Jan 82 88
33. D.J. Wallace, K. Kalunian, M.A. Petri, V. Strand, F.A. Houssiau, and M. Pike Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Annals of the Rheumatic 2013 Jan 12 10.1136/annrheumdis-2012-202760
34. M.H. Cardiel, J.A. Tumlin, R.A. Furie, D.J. Wallace, T. Joh, and M.D. Linnik Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial Arthritis & Rheumatism 58 8 2008 Aug 2470 2480
35. M.A. Petri, R.G. Lahita, R.F. van Vollenhoven, J.T. Merrill, M. Schiff, and E.M. Ginzler Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial Arthritis & Rheumatism 46 7 2002 Jul 1820 1829
36. C.S. Yee, D.A. Isenberg, A. Prabu, K. Sokoll, L.S. Teh, and A. Rahman BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 Annals of the Rheumatic 67 6 2008 Jun 873 876
37. C.S. Yee, V. Farewell, D.A. Isenberg, B. Griffiths, L.S. Teh, and I.N. Bruce The BILAG-2004 index is sensitive to change for assessment of SLE disease activity Rheumatology (Oxford) 48 6 2009 Jun 691 695
38. D.A. Isenberg, A. Rahman, E. Allen, V. Farewell, M. Akil, and I.N. Bruce BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus Rheumatology (Oxford) 44 7 2005 Jul 902 906
39. L. Cresswell, C.S. Yee, V. Farewell, A. Rahman, L.S. Teh, and B. Griffiths Numerical scoring for the Classic BILAG index Rheumatology (Oxford) 48 12 2009 Dec 1548 1552
40. D.J. Wallace, C. Gordon, V. Strand, K. Hobbs, M. Petri, and K. Kalunian Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up 2013 Mar 28 Rheumatology Oxford
41. S. Manzi, J. Sanchez-Guerrero, J.T. Merrill, R. Furie, D. Gladman, and S.V. Navarra Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Annals of the Rheumatic 71 11 2012 Nov 1833 1838
42. J.T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, and D.J. Wallace The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis & Rheumatism 62 10 2010 Oct 3077 3087
43. M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, and D.A. Isenberg B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology (Oxford) 44 12 2005 Dec 1542 1545
44. S.A. Wright, F.M. O'Prey, M.T. McHenry, W.J. Leahey, A.B. Devine, and E.M. Duffy A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus Annals of the Rheumatic 67 6 2008 Jun 841 848
45. D. Fernandez, E. Bonilla, N. Mirza, B. Niland, and A. Perl Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus Arthritis & Rheumatism 54 9 2006 Sep 2983 2988
46. B. Griffiths, P. Emery, V. Ryan, D. Isenberg, M. Akil, and R. Thompson The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE Rheumatology (Oxford) 49 4 2010 Apr 723 732
47. E.M. Ginzler, D. Wofsy, D. Isenberg, C. Gordon, L. Lisk, and M.A. Dooley Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial Arthritis & Rheumatism 62 1 2010 Jan 211 221
48. T. Rose, A. Grutzkau, H. Hirseland, D. Huscher, C. Dahnrich, and A. Dzionek IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus Annals of the Rheumatic 72 10 2013 Oct 1 1639 1645
49. M.V. Madureira Silva, G.T. Moscoso-Solorzano, S.K. Nishida, and G. Mastroianni-Kirsztajn Serum Beta 2-microglobulin/cystatin C index: a useful biomarker in lupus nephritis? Nephron Extra 2 1 2012 Jan 169 176
50. T. Rubinstein, M. Pitashny, B. Levine, N. Schwartz, J. Schwartzman, and E. Weinstein Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis Rheumatology (Oxford) 49 5 2010 May 960 971
51. S.D. Marks, C. Pilkington, P. Woo, and M.J. Dillon The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus Rheumatology (Oxford) 43 9 2004 Sep 1186 1189
52. C.S. Yee, M. Akil, M. Khamashta, R. Bessant, R. Kilding, and I. Giles The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients Rheumatology (Oxford) 51 10 2012 Oct 1877 1880
53. J. Merrill, J. Buyon, R. Furie, K. Latinis, C. Gordon, and H.J. Hsieh Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER) Lupus 20 7 2011 Jun 709 716
54. R.A. Furie, M.A. Petri, D.J. Wallace, E.M. Ginzler, J.T. Merrill, and W. Stohl Novel evidence-based systemic lupus erythematosus responder index Arthritis & Rheumatism 61 9 2009 Sep 15 1143 1151
55. K.M. Luijten, J. Tekstra, J.W. Bijlsma, and M. Bijl The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment Autoimmunity Reviews 11 5 2012 Mar 326 329
56. R.F. van Vollenhoven, M.A. Petri, R. Cervera, D.A. Roth, B.N. Ji, and C.S. Kleoudis Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response Annals of the Rheumatic 71 8 2012 Aug 1343 1349
57. V. Strand, and A.D. Chu Measuring outcomes in systemic lupus erythematosus clinical trials Pharmacoeconomics & Outcomes Research 11 4 2011 Aug 455 468
58. M. Petri, N. Kasitanon, S.S. Lee, K. Link, L. Magder, and S.C. Bae Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index Arthritis & Rheumatism 58 6 2008 Jun 1784 1788
59. Z. Touma, D.D. Gladman, D. Ibanez, and M.B. Urowitz SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years Lupus 21 12 2012 Oct 1305 1311
60. Z. Touma, M.B. Urowitz, S. Taghavi-Zadeh, D. Ibanez, and D.D. Gladman Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months Rheumatology (Oxford) 51 10 2012 Oct 1814 1819
61. M. Petri, R.A. Brodsky, R.J. Jones, D. Gladstone, M. Fillius, and L.S. Magder High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial Arthritis & Rheumatism 62 5 2010 May 1487 1493
62. D.A. Isenberg, E. Allen, V. Farewell, D. D'Cruz, G.S. Alarcon, and C. Aranow An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA Annals of the Rheumatic 70 1 2011 Jan 54 59
63. C. Gordon, N. Sutcliffe, J. Skan, T. Stoll, and D.A. Isenberg Definition and treatment of lupus flares measured by the BILAG index Rheumatology (Oxford) 42 11 2003 Nov 1372 1379
64. A. Ho, L.S. Magder, S.G. Barr, and M. Petri Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus Arthritis & Rheumatism 44 10 2001 Oct 2342 2349
65. A.J. Steiman, D.D. Gladman, D. Ibanez, and M.B. Urowitz Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome The Journal of Rheumatology 37 9 2010 Sep 1822 1827
66. M.A. Petri, R.F. van Vollenhoven, J. Buyon, R.A. Levy, S.V. Navarra, and R. Cervera Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the Phase 3 belimumab trials Arthritis & Rheumatism 65 8 2013 Aug 2143 2153
67. M. Nikpour, M.B. Urowitz, D. Ibanez, and D.D. Gladman Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus Arthritis & Rheumatism 61 9 2009 Sep 15 1152 1158
68. J.P. Buyon, M.A. Petri, M.Y. Kim, K.C. Kalunian, J. Grossman, and B.H. Hahn The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial Annals of Internal Medicine 142 12 Pt 1 2005 Jun 21 953 962
69. M. Petri, J. Buyon, K. Kalunian, M. Urowitz, V. Strand, and J. Merrill Revision of the SELENA flare index Arthritis and Rheumatism 60 2009 Oct 1 16 21
70. S.A. Chambers, E. Allen, A. Rahman, and D. Isenberg Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years Rheumatology (Oxford) 48 6 2009 Jun 673 675
71. D.D. Gladman, C.H. Goldsmith, M.B. Urowitz, P. Bacon, P. Fortin, and E. Ginzler The systemic lupus international collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison The Journal of Rheumatology 27 2 2000 Feb 373 376
72. D. Isenberg, and R. Ramsey-Goldman Assessing patients with lupus: towards a drug responder index Rheumatology (Oxford) 38 11 1999 Nov 1045 1049
73. T. Stoll, N. Sutcliffe, R. Klaghofer, and D.A. Isenberg Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: a prospective study Annals of the Rheumatic 59 10 2000 Oct 832 835
74. P. Rahman, D.D. Gladman, M.B. Urowitz, D. Hallett, and L.S. Tam Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus Lupus 10 2 2001 93 96
75. T. Stoll, N. Sutcliffe, J. Mach, R. Klaghofer, and D.A. Isenberg Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study Rheumatology (Oxford) 43 8 2004 Aug 1039 1044
76. R. Lopez, J.E. Davidson, M.D. Beeby, P.J. Egger, and D.A. Isenberg Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort Rheumatology (Oxford) 51 3 2012 Mar 491 498
77. L. Turano Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus: understanding management strategies Journal of Cardiovascular Nursing 28 1 2013 Jan 48 53
78. Z.S. Bonakdar, N. Mohtasham, and M. Karimifar Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus Journal of Research in Medical Sciences 16 Suppl. 1 2011 Mar S427 S432
79. I.A. Tarasova, M.M. Ivanova, A.P. Zhorniak, and V.A. Nasonova Significance of damage index in predicting systemic lupus erythematosus outcome Ter Arkh 75 1 2003 59 62
80. J. Thumboo, and V. Strand Health-related quality of life in patients with systemic lupus erythematosus: an update Annals Academy of Medicine Singapore 36 2 2007 Feb 115 122
81. K. McElhone, J. Abbott, and L.S. Teh A review of health related quality of life in systemic lupus erythematosus Lupus 15 10 2006 633 643
82. S. Pettersson, M. Lovgren, L.E. Eriksson, C. Moberg, E. Svenungsson, and I. Gunnarsson An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life Scandinavian The Journal of Rheumatology 41 5 2012 Oct 383 390
83. S.V. Navarra, R.M. Guzman, A.E. Gallacher, S. Hall, R.A. Levy, and R.E. Jimenez Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 9767 2011 Feb 26 721 731
84. K. McElhone, J. Abbott, J. Shelmerdine, I.N. Bruce, Y. Ahmad, and C. Gordon Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus Arthritis & Rheumatism 57 6 2007 Aug 15 972 979
85. K. McElhone, M. Castelino, J. Abbott, I.N. Bruce, Y. Ahmad, and J. Shelmerdine The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus The Journal of Rheumatology 37 11 2010 Nov 2273 2279
86. K.P. Leong, K.O. Kong, B.Y. Thong, E.T. Koh, T.Y. Lian, and C.L. Teh Development and preliminary validation of a systemic lupus erythematosus- specific quality-of-life instrument (SLEQOL) Rheumatology (Oxford) 44 10 2005 Oct 1267 1276
87. L.C. Doward, S.P. McKenna, D. Whalley, A. Tennant, B. Griffiths, and P. Emery The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus Annals of the Rheumatic 68 2 2009 Feb 196 200
88. J. Yazdany Health-related quality of life measurement in adult systemic lupus erythematosus: lupus quality of life (LupusQoL), systemic lupus erythematosus-specific quality of life questionnaire (SLEQOL), and systemic lupus erythematosus quality of life questionnaire (L-QoL) Arthritis Care & Research (Hoboken) 63 Suppl. 11 2011 Nov S413 S419